ensuring knowledge, enhancing quality
A 'not-for-profit' organisation,
run for pharmaceutical analysts by pharmaceutical analysts


Thursday 15th March 2018
Continuous manufacturing
Royal Society of Chemistry, London
Purpose of meeting:
Continuous manufacturing offers great promise in improving productivity, efficiency and the intrinsic quality of pharmaceutical products. However, despite strong regulatory support aimed at encouraging the early adoption of new technologies, which in turn would facilitate the application of modern quality management techniques to all aspects of pharmaceutical production and quality assurance; uptake by Industry has been very slow.
The first NDA approval using continuous manufacturing for a fixed dose combination tablet product, Orkambi® (lumacaftor/ivacaftor), was approved by the FDA and EMA during 2015. Prezista® was the first supplemental NDA approval (2016) for changing from an established batch process to a continuous manufacturing process.
This symposium will critically examine some of the challenges and opportunities that arise from adopting continuous manufacturing. Leading regulators, industrialists and academics will be sharing their experiences in the development, manufacturing and quality assurance of continuous manufacturing.
Why has industry been so slow to embrace this new approach to manufacturing?
What are some of the regulatory challenges?
What are some of the quality challenges, particularly from the perspective of the QP?
What are some of the data challenges that arise in a “big data” scenario?
How do we ensure that our personnel are appropriately trained to allow them to move from “batch” to “continuous” manufacturing?
What are some of the PAT applications to be found in a continuous manufacturing process?
Better understanding of continuous manufacturing and the advancement of PAT will ultimately result in real time release processes. Continuous manufacturing processes have a small footprint so engender more flexible use of space in the factory of the future. Continuous manufacturing can better cope with the peaks/troughs that routinely occur in a supply/demand market.
Proposed outcomes:
You will gain the latest insights into the regulatory and manufacturing challenges that arise from continuously manufactured products and processes. You will better understand the critical role of chemometrics, PAT and at-line analysis for the continuous monitoring and control of these processes. You will be able to network with experts across industry, academia and the regulators.

If you are considering attending this event, you will be interested in reading an article on continuous manufacturing.
Download the article

Posters are welcome. Please submit to Dave Elder: davidelder2110@gmail.com

Dr Montserrat Casadevall-Callis - GlaxoSmithKline
Dr Chris Clarke - GlaxoSmithKline
Dr Richard Hart - AstraZeneca
Prof David Littlejohn - Strathclyde University
Petter Moree - OSIsoft
Dr Ron Ogilvie - Pfizer
Dr Colm Reddington - MHRA
Dr Patrick Wahl - RCPE



You will have access to materials for meetings that you have attended.

You will need to Sign In to activate access to your additional options.
Once Signed in, click on RESOURCES and look under MY PAST MEETINGS.

Symposium - October 2011

Delegates at a symposium held at the Royal Pharmaceutical Society

© Joint Pharmaceutical Analysis Group 2018
Website by Delta Consultancy Services